News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Watson Pharmaceuticals, Inc. (WPI) Close to $7 Billion Actavis Drug Deal: Sources


3/21/2012 3:21:00 PM

Watson Pharmaceuticals Inc (WPI.N) is close to buying Swiss-based Actavis for around $7 billion, marking the latest deal between generics companies racing to achieve economies of scale, three sources familiar with the matter said. The deal would involve U.S.-based Watson, already among the world's five largest generic drugmakers, paying between 5.0 billion and 5.5 billion euros ($6.6-7.3 billion) for Actavis, a business not much smaller than its own, the sources said. After rapid expansion in the early 2000s, Actavis underwent a leveraged buyout in 2007 by Icelandic tycoon Bjorgolfur Thor Bjorgolfsson, which ultimately left Deutsche Bank (DBKGn.DE) holding billions of euros of its debt.

Read at Reuters
Read at BusinessWeek
Read at Wall Street Journal
Read at Market Watch
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES